顶级期刊2009.5的抗病毒药物成本疗效比研究，tenofovir完胜。

cshbv

Modeling the cost-effectiveness of different oral antiviral therapies in patients with chronic hepatitis B
http://www.ncbi.nlm.nih.gov/pubmed/19576651

1: J Hepatol. 2009 May 20. [Epub ahead of print]
Buti M, Brosa M, Casado MA, Rueda M, Esteban R.
Servicio de Hepatologi a, Hospital Vall d'Hebrón and Ciber-ehd del Instituto Carlos III, Barcelona, Spain.
BACKGROUND/AIMS: Chronic hepatitis B (CHB) is a common disease associated with high morbidity, mortality and impact on healthcare costs. Several oral antiviral therapies can lead to complete virologic response, which is associated with prevention of disease progression. The aim of this study was to estimate the cost-effectiveness of the oral antiviral treatments lamivudine, adefovir, telbivudine, entecavir and tenofovir, in patients with CHB. METHODS: A Markov model was used to project the lifetime complications and costs in cohorts of both HBeAg-positive and HBeAg-negative CHB patients treated with one of the above drugs or no treatment. Rescue therapy with two different combination therapies (adefovir plus lamivudine or tenofovir plus entecavir) with their corresponding costs and efficacy rates was also considered. The probabilities of disease progression were based on serum HBV DNA levels. Disease and complication costs were assessed using the perspective of the Spanish National Health System. RESULTS: The highest rate of virologic response was obtained with tenofovir, and this translated to its higher life years saved (LYS) and quality adjusted life years (QALY) compared with the rest of the alternatives in HBeAg-positive and HBeAg-negative patients. Tenofovir is associated with lower costs and higher efficacy over entecavir, telbivudine and adefovir in HBeAg-positive patients, and telbivudine and entecavir in HBeAg-negative patients. The incremental cost-effectiveness ratios with respect to the rest of the alternatives are below the common reference efficiency threshold of 30,000euro per LYS/QALY. CONCLUSION: In chronic HBV infected patients, tenofovir is a cost-effective or even cost-saving strategy compared with other available treatment options for CHB.

比较疗法:
1. no treatment, 2. lamivudine, 3. adefovir, 4. telbivudine, 5. entecavir 6. tenofovir, 7. adefovir plus lamivudine, 8. tenofovir plus entecavir.
比较标准:
1. both HBeAg-positive and HBeAg-negative
2. cost-effectiveness.
比较结果:
1. The highest rate of virologic response (higher life years saved, quality adjusted life years): tenofovir.
2. Tenofovir is associated with lower costs and higher efficacy over entecavir, telbivudine and adefovir in HBeAg-positive patients.
3. Tenofovir is associated with lower costs and higher efficacy over telbivudine and entecavir in HBeAg-negative patients.
4. The incremental cost-effectiveness ratios with respect to the rest of the alternatives are below the common reference efficiency threshold of 30,000euro per LYS/QALY.

结论:
In chronic HBV infected patients, tenofovir is a cost-effective or even cost-saving strategy compared with other available treatment options for CHB.


希望对大家有用。

[ 本帖最后由 cshbv 于 2009-7-14 11:46 编辑 ]

lwkais

拜托，翻译下，看不懂！

手牵手

建模的成本效益不同口服抗病毒疗法治疗慢性乙型肝炎
Buti M , Brosa M , Casado MA , Rueda M , Esteban R . Buti M ， Brosa M ， Casado马 ， 鲁埃达M ， 埃斯特R 。

Servicio de Hepatologi a, Hospital Vall d'Hebrón and Ciber-ehd del Instituto Carlos III, Barcelona, Spain.事务处Hepatologi 1日，医院瓦尔德希布伦和Ciber -弹流删除卡洛斯三世研究所，西班牙巴塞罗那。

BACKGROUND/AIMS: Chronic hepatitis B (CHB) is a common disease associated with high morbidity, mortality and impact on healthcare costs.背景/目的：慢性乙型肝炎（ CHB ）是一种常见疾病相关的高发病率，死亡率和医疗费用的影响。 Several oral antiviral therapies can lead to complete virologic response, which is associated with prevention of disease progression.口服抗病毒药物治疗几种可导致完全病毒学应答，这与预防疾病的发展。 The aim of this study was to estimate the cost-effectiveness of the oral antiviral treatments lamivudine, adefovir, telbivudine, entecavir and tenofovir, in patients with CHB.本研究的目的是要估计成本效益的口头拉米夫定抗病毒治疗，阿德福韦，替比夫定，恩替卡韦和替诺福韦，慢性乙型肝炎患者。 METHODS: A Markov model was used to project the lifetime complications and costs in cohorts of both HBeAg-positive and HBeAg-negative CHB patients treated with one of the above drugs or no treatment.方法： Markov模型被用于项目的生命周期成本的并发症和同伙都HBeAg阳性和HBeAg阴性慢性乙型肝炎治疗的患者之一，上述药物或任何治疗。 Rescue therapy with two different combination therapies (adefovir plus lamivudine or tenofovir plus entecavir) with their corresponding costs and efficacy rates was also considered.抢救治疗的是两个不同的联合疗法（阿德福韦加拉米夫定或替加卡韦）及其相应的成本和效率也被认为。 The probabilities of disease progression were based on serum HBV DNA levels.的概率疾病的发展是基于血清HBV DNA水平。 Disease and complication costs were assessed using the perspective of the Spanish National Health System.疾病及并发症的费用分摊使用的角度，对西班牙国家的卫生系统。 RESULTS: The highest rate of virologic response was obtained with tenofovir, and this translated to its higher life years saved (LYS) and quality adjusted life years (QALY) compared with the rest of the alternatives in HBeAg-positive and HBeAg-negative patients.结果：发病率最高的病毒学应答获得与泰诺福韦，这转化为较高的生活里保存（赖氨酸）和质量调整寿命年（ QALY ） ，而其余的替代品在HBeAg阳性和HBeAg阴性的患者。 Tenofovir is associated with lower costs and higher efficacy over entecavir, telbivudine and adefovir in HBeAg-positive patients, and telbivudine and entecavir in HBeAg-negative patients.泰诺福韦与更低的成本和更高的效率超过卡韦，替比夫定和阿德福韦在HBeAg阳性患者和替比夫定和恩替卡韦在HBeAg阴性患者。 The incremental cost-effectiveness ratios with respect to the rest of the alternatives are below the common reference efficiency threshold of 30,000euro per LYS/QALY.增量成本效益比对其他的替代品低于共同参考效率门槛三点○万欧元每赖氨酸/ QALY 。 CONCLUSION: In chronic HBV infected patients, tenofovir is a cost-effective or even cost-saving strategy compared with other available treatment options for CHB.结论：在慢性HBV感染患者，泰诺福韦是一个具有成本效益，甚至成本节约战略，与其他可用于慢性乙型肝炎的治疗方法。

dickens_yu

不知道替诺福韦啥时候在中国上市

走遍四方

原帖由 dickens_yu 于 2009-7-29 07:54 发表
不知道替诺福韦啥时候在中国上市

有谁知道bu？

80后的悲伤

能够去除英文，来一纯汉语的么

齐欢畅2

好帖，顶了

齐欢畅2

tenofovir完胜。
比较疗法:
1. no treatment, 2. lamivudine, 3. adefovir, 4. telbivudine, 5. entecavir 6. tenofovir, 7. adefovir plus lamivudine, 8. tenofovir plus entecavir.
比较标准:
1. both HBeAg-positive and HBeAg-negative
2. cost-effectiveness.
比较结果:
1. The highest rate of virologic response (higher life years saved, quality adjusted life years): tenofovir.
2. Tenofovir is associated with lower costs and higher efficacy over entecavir, telbivudine and adefovir in HBeAg-positive patients.
3. Tenofovir is associated with lower costs and higher efficacy over telbivudine and entecavir in HBeAg-negative patients.
4. The incremental cost-effectiveness ratios with respect to the rest of the alternatives are below the common reference efficiency threshold of 30,000euro per LYS/QALY.

结论:
In chronic HBV infected patients, tenofovir is a cost-effective or even cost-saving strategy compared with other available treatment options for CHB.

虎豆

第一次见到这么多版主

duqingwu

好帖好帖好帖